Cullinan outlines Q4 2026 data readouts for CLN-978, velinotamig, CLN-049

Cullinan Therapeutics, Inc.

CLN-978 (CD19xCD3 TCE): multi-dose and single target dose data for SLE, RA, Sjögren's disease in December.
Velinotamig (BCMAxCD3 TCE): Genrix Bio Phase 1 SLE multi-dose data at ACR Convergence 2026 on Nov 8, 2026.
CLN-049 (FLT3xCD3 TCE): updated Phase 1 dose-escalation data in relapsed/refractory AML in December.
CEO notes successful FDA meeting for CLN-049; registrational Phase 2 study planned to initiate.
All data are from ongoing Phase 1 trials; no efficacy results disclosed yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.